STING unlocks CD4⁺ T cell immunity in pancreatic cancer.

IF 56.1 1区医学 Q1 CELL BIOLOGY

Cancer Cell Pub Date : 2026-07-13 Epub Date: 2026-06-11 DOI:10.1016/j.ccell.2026.05.009

Bastian Kruse, Ben P Leonhardt, Jan P Böttcher

引用次数: 0

Abstract

Pancreatic ductal adenocarcinomas (PDACs) are lethal cancers resistant to immunotherapies. In this issue of Cancer Cell, Kureshi et al. show that combining checkpoint blockade with STING-mediated innate immune stimulation unlocks cDC2-driven CD4⁺ T cell immunity in mice, promoting PDAC immune control. This cellular axis may be exploited for PDAC therapy.

查看原文本刊更多论文

STING解锁胰腺癌中CD4 + T细胞免疫

胰腺导管腺癌（pdac）是一种对免疫治疗有耐药性的致命癌症。Kureshi等人在本期《Cancer Cell》中表明，检查点阻断联合sting介导的先天免疫刺激可解锁小鼠cdc2驱动的CD4+ T细胞免疫，促进PDAC免疫控制。该细胞轴可用于PDAC治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Cell 医学-肿瘤学

CiteScore

55.20

自引率

1.20%

发文量

179

审稿时长

4-8 weeks

期刊介绍： Cancer Cell is a journal that focuses on promoting major advances in cancer research and oncology. The primary criteria for considering manuscripts are as follows: Major advances: Manuscripts should provide significant advancements in answering important questions related to naturally occurring cancers. Translational research: The journal welcomes translational research, which involves the application of basic scientific findings to human health and clinical practice. Clinical investigations: Cancer Cell is interested in publishing clinical investigations that contribute to establishing new paradigms in the treatment, diagnosis, or prevention of cancers. Insights into cancer biology: The journal values clinical investigations that provide important insights into cancer biology beyond what has been revealed by preclinical studies. Mechanism-based proof-of-principle studies: Cancer Cell encourages the publication of mechanism-based proof-of-principle clinical studies, which demonstrate the feasibility of a specific therapeutic approach or diagnostic test.